KBI Biopharma, Inc is a global Contract Development and Manufacturing Organization (CDMO) that specializes in biopharmaceutical development and manufacturing services. They offer a comprehensive range of services, including cell line development, process development, analytical development, formulation development, characterization, clinical manufacturing, and commercial manufacturing for both mammalian and microbial-based expression systems. With their science-driven approach and customer-focused mindset, KBI Biopharma is dedicated to delivering innovative biologic solutions that positively impact the lives of patients worldwide.
KBI Biopharma is known for their cutting-edge technologies, such as the SUREtechnology Platform powered by Selexis, which provides premium, stable, and integrated CHO-based cell line development. They also offer the KBI PUREplatform, a new standard of E. Coli expression for clean and efficient therapeutic protein production. With their versatile, scalable, and efficient services, KBI Biopharma is committed to supporting the development and manufacturing of new biopharmaceuticals, including cell therapy for unique autologous and allogeneic therapeutic development.
Generated from the website